[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endothelial-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endothelial-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,86,119,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100650441","black-forest-cocoa-flavanol-supplementation-and-health-trial-100650441",false,"NCT07747714","Black Forest Cocoa Flavanol Supplementation and Health Trial","Inclusion Criteria:\n\n* Male participants aged 30 to 75 years.\n* Able and willing to provide written informed consent.\n* Generally healthy, as determined by medical history and screening assessments.\n* Willing and able to comply with all study procedures, including blood collection, daily study-product intake, and required study visits.\n* Willing to consume the assigned cocoa flavanol supplement or low-flavanol control product once daily for the duration of the study.\n* Willing to provide peripheral blood samples at baseline and at the end of the intervention.\n* Willing to maintain generally stable dietary, exercise, sleep, medication, and supplement habits during the study.\n* Willing to refrain from initiating new supplements, restrictive diets, fasting regimens, or major exercise programs during the study.\n* Not currently taking medications or supplements known to substantially affect vascular function, nitric oxide pathways, inflammation, oxidative stress, or coagulation, unless approved by the investigator.\n\nExclusion Criteria:\n\n* Female biological sex.\n* Younger than 30 years or older than 75 years.\n* Known cardiovascular, metabolic, renal, hepatic, inflammatory, or autoimmune disease, including coronary artery disease, diabetes mellitus, chronic kidney disease, chronic liver disease, rheumatoid arthritis, or another clinically significant inflammatory disorder.\n* Hypertension requiring prescription medication.\n* Active infection, acute illness, or other clinically significant medical condition at screening or baseline.\n* Current use of medications or supplements that may substantially affect vascular function, inflammatory biomarkers, nitric oxide pathways, oxidative stress, or coagulation, including chronic nonsteroidal anti-inflammatory drugs, systemic corticosteroids, anticoagulants, antiplatelet drugs, prescription immunomodulatory agents, phosphodiesterase-5 inhibitors, or high-dose antioxidant supplements, unless approved by the investigator.\n* Known allergy, hypersensitivity, or intolerance to cocoa, chocolate, cocoa flavanols, or any ingredient in either study product.\n* Gastrointestinal disease or condition that may interfere with digestion or absorption of the study product, including celiac disease, inflammatory bowel disease, active gastritis, or a clinically significant malabsorption disorder.\n* Current smoking or vaping of nicotine or cannabis products.\n* Major psychiatric illness, cognitive impairment, or another condition that may interfere with informed consent, adherence, or completion of study procedures.\n* Alcohol or drug abuse within the previous 12 months that, in the investigator's judgment, may affect participant safety or study adherence.\n* Participation in another interventional clinical study within 30 days before screening.\n* Plans to begin a new medication, supplement, restrictive diet, fasting regimen, or major exercise program during the study period.\n* Any condition or circumstance that, in the investigator's judgment, would increase participant risk, interfere with study procedures, compromise adherence, or affect interpretation of the study results.",true,"MALE","30 Years","75 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, double-blind, controlled clinical trial will evaluate the effects of daily cocoa flavanol supplementation on vascular and inflammatory biomarkers in healthy adult men aged 30 to 75 years. Participants will be randomized to receive either a cocoa flavanol supplement or a nutrient-matched low-flavanol control product for 4 to 8 weeks. The study will assess changes in inflammatory biomarkers, endothelial function, oxidative stress markers, vascular measurements, and circulating endothelial progenitor cell-related markers. Optional assessments include flow-mediated dilation and single-cell RNA sequencing of peripheral blood mononuclear cells to explore mechanistic biological responses to cocoa flavanol supplementation.",[27,28,29,30],"Endothelial Function","Oxidative Stress","Inflamation","Vascular Health",[32,33,34,35,36,37,38,39,40,41,42,43],"Cocoa Flavanols","Flavanol Supplementation","Endothelial Biomarkers","Vascular Function","Endothelial Progenitor Cells","Nitric Oxide","Inflammatory Biomarkers","Pulse Wave Velocity","Flow-Mediated Dilation","Nutrition Study","Dietary Supplement","Healthy Adults","NOT_YET_RECRUITING","2026-07-31",{"date":47,"type":48},"2026-08-05","ACTUAL",{"date":50,"type":21},"2026-08-15",{"date":52,"type":21},"2027-01",{"name":54,"class":55},"The Black Forest LLC","INDUSTRY",2,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":15,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100647966","early-phase-1-antidepressant-therapy-for-improved-blood-vessel-health-after-preeclampsia-100647966","NCT07715669","Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia","Role of Antidepressant Therapy to Improve Vascular Function After Preeclampsia","Inclusion Criteria:\n\n* 18-24 years old,\n* 12 weeks - 5 years post pregnancy\n* one of the following:\n* history of a normal pregnancy with a current diagnosis of depression,\n* history of a normal pregnancy without a current diagnosis of depression,\n* history of a preeclamptic pregnancy with a current diagnosis of depression\n* history of preeclamptic pregnancy without a current diagnosis of depression.\n\nExclusion Criteria:\n\n* history of cardiovascular, metabolic, and\u002For skin diseases\n* current or history of tobacco\u002Fnicotine\u002F e-cigarette use\n* history of gestational diabetes\n* current antihypertensive or cholesterol-lowering medication\n* currently pregnant\n* allergy to materials used during the experiment (e.g. latex),\n* known allergy to study drugs\n* currently using SSRI medications","FEMALE","18 Years","45 Years",{"count":68,"type":21},40,[70],"EARLY_PHASE1","Preeclampsia is a condition in pregnancy where a woman develops high blood pressure and other complications. Women who develop preeclampsia are 4 times more likely to have heart disease later in life. They are also more likely to have depression after pregnancy. Why they are more likely to develop these conditions is not known. It may be because their blood vessels were damaged during pregnancy. Changes in blood vessel health can predict heart disease. These changes have been recorded after pregnancy in women who had preeclampsia. These changes have also been recorded in women who have depression. In the previous phase of this award, we found that women who had preeclampsia in pregnancy had changes in blood vessel health after pregnancy. We also found that if these women were taking a medicine to treat depression, their blood vessel health was normal. This could mean that treatment for depression can also increase blood vessel health in women who had preeclampsia. In this project we will study how changes in blood vessel health are related to preeclampsia and depression in women who have had both. We will also study how medicine to treat depression can improve blood vessel health after preeclampsia. We will do this by measuring how blood vessels work in women who have had preeclampsia compared to women who did not, and in women who have depression and women who do not. This will tell us more about why risk for depression and heart disease is higher in women who have had preeclampsia. It will also help us understand if medicine for depression can reduce cardiovascular disease risk after preeclampsia.",[73,27],"Preeclampsia","RECRUITING","2026-07-27",{"date":77,"type":48},"2026-07-29",{"date":79,"type":21},"2026-08-30",{"date":81,"type":21},"2027-06",{"name":83,"class":84},"Anna Stanhewicz, PhD","OTHER",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":15,"sex":94,"minAge":65,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":85},"100648895","endothelial-extracellular-vesicles-as-biomarkers-of-endothelial-activation-in-adults-with-newly-diagnosed-hypertension-100648895","NCT07728630","Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Adults With Newly Diagnosed Hypertension","Endothelial Extracellular Vesicles as Biomarkers of Blood Pressure-Induced Endothelial Activation in Adults With Newly Diagnosed Untreated Hypertension","HYPER-endoEV-a","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Ability and willingness to provide written informed consent.\n* Normotensive individuals or individuals with newly diagnosed, previously untreated primary hypertension, classified according to the European Society of Hypertension (ESH) guidelines.\n* Ability to comply with all study procedures.\n\nExclusion Criteria:\n\n* Secondary hypertension.\n* Previous treatment with antihypertensive medication.\n* History of cardiovascular disease (except newly diagnosed primary hypertension in the hypertensive group).\n* Diabetes mellitus.\n* Chronic kidney disease.\n* Cerebrovascular disease.\n* Peripheral arterial disease.\n* Acute or chronic inflammatory or infectious disease.\n* Active malignancy.\n* Pregnancy or breastfeeding.\n* Current use of oral contraceptives, hormone replacement therapy, or medications known to affect endothelial function.\n* Inability or unwillingness to provide informed consent.","ALL",{"count":96,"type":21},80,"OBSERVATIONAL","Hypertension is associated with endothelial dysfunction, an early event in the development of cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation and vascular injury; however, their relationship with blood pressure and microvascular endothelial function in untreated hypertension remains insufficiently understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive adults and adults with newly diagnosed, untreated primary hypertension. In addition, the study will investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and established circulating biomarkers of endothelial activation. The findings may improve understanding of the role of EEVs in early hypertension and support their potential use as non-invasive biomarkers of endothelial dysfunction and cardiovascular risk.",[100,27],"Hypertension",[100,102,103,104,105,106,107,108,109,110,35],"Primary Hypertension","Endothelial Dysfunction","Endothelial Extracellular Vesicles","Extracellular Vesicles","Endothelial Activation","Biomarkers","Microvascular Function","Laser Doppler Flowmetry","Post-Occlusive Reactive Hyperemia","2026-07-22",{"date":75,"type":48},{"date":114,"type":48},"2026-05-01",{"date":116,"type":21},"2029-09-30",{"name":118,"class":84},"Josip Juraj Strossmayer University of Osijek",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":94,"minAge":65,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":85},"100645419","effect-of-platelet-concentrate-transfusion-on-microcirculatory-endothelial-function-in-intensive-care-unit-100645419","NCT07682246","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT.","PLATOMIR","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Admitted to intensive care\n* Requires prophylactic platelet transfusion for thrombocytopenia\n* Enrolled in a social security program\n* No objection to participating in the study\n\nExclusion Criteria:\n\n* Recent platelet or red blood cell transfusion (\\\u003C 24 hours)\n* Need for urgent red blood cell transfusion due to active bleeding\n* Patient under guardianship or conservatorship\n* Significant peripheral edema",{"count":128,"type":21},60,"This study aims to investigate the impact of platelet concentrate (PC) transfusions on endothelial function and the systemic inflammatory response in thrombopenic patients admitted to intensive care who require prophylactic platelet transfusions.\n\nEndothelial function will be measured using a laser Doppler device coupled with an acetylcholine iontophoresis system that is applied to the skin.",[131,132,133,27],"Thrombocytopenia","Prophylactic Platelet Transfusion","Platelet Transfusion",[135,136,133,27,137,138,139,140],"ICU","intensive care","endothelial biomarkers","systemic inflammation","oxidative stress","peripheral tissue perfusion","2026-06-26",{"date":143,"type":48},"2026-07-02",{"date":145,"type":21},"2026-07",{"date":147,"type":21},"2027-07",{"name":149,"class":84},"Assistance Publique - Hôpitaux de Paris",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":15,"sex":94,"minAge":65,"maxAge":17,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":85},"100554496","early-phase-1-comparing-approaches-to-assess-nitric-oxide-dependent-cutaneous-vasodilation-100554496","NCT06499844","Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation","CAP NOVA","Inclusion Criteria:\n\n* men and women\n* 18-30 years of age\n\nExclusion Criteria:\n\n* Current or recent (within 8 wks) use of medication that could conceivably alter microvascular function \\[including (but not limited to) stimulants, antihypertensives, HMG-CoA reductase inhibitors\\]\n* Changes or alterations in medication status (starting a new, additional, or different medication or changing the dose of a current medication)\n* Unstable or diagnosed chronic clinical disease, including cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological disease (e.g., hypertension, heart disease, diabetes, hyperlipidemia, psoriasis)\n* Body mass index \\\u003C18.5 or \\>35 kg\u002Fm2\n* Pregnancy (including a positive urine pregnancy test) or breast-feeding\n* Known allergies to pharmacological agents or study drugs\n* Non-English-speaking. Participants need to understand English to follow instructions and comply with procedures conducted during the screening and experimental visits.",{"count":158,"type":21},56,[70],"The increase in skin blood flow in response to rapid local heating of the skin (i.e., cutaneous vasodilation) is commonly used to assess nitric oxide (NO)-dependent dilation and overall microvascular function. Historically, rapid local heating to 42°C was considered the standard approach for these assessments. More recently, many investigators have adopted rapid local to 39°C instead, based on its larger dependency on NO and therefore improved ability to quantify NO-dependent dilation without the use of pharmacological techniques. However, to date, only one direct methodological comparison between these protocols has been performed.\n\nIn this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a nickel-sized area of the skin in young adults ages 18 - 30 years old. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, the investigators also have participants fill out a variety of surveys to assess things such as sleep quality, physical activity, daily stressors, etc.",[27],"2025-08-19",{"date":164,"type":48},"2025-08-24",{"date":166,"type":48},"2024-08-01",{"date":168,"type":21},"2026-09",{"name":170,"class":84},"University of Iowa"]